Summary | Biopharmaceutical venture capital investment climbed
from $4.52 billion in 2013 to $5.29 billion in 2014, a 17%
increase, according to Dow Jones VentureSource.Joel Marcus,
chief executive of Alexandria Real Estate Equities Inc., has
been in biotech since its early days. From 1984 to 1994, he had
an law career with expertise in the biopharmaceutical industry ...
from $4.52 billion in 2013 to $5.29 billion in 2014, a 17%
increase, according to Dow Jones VentureSource.Joel Marcus,
chief executive of Alexandria Real Estate Equities Inc., has
been in biotech since its early days. From 1984 to 1994, he had
an law career with expertise in the biopharmaceutical industry ...
blogs.wsj.com | 30 March 2015